References
- Johnson RT, Gibbs CJ Jr. Creutzfeldt–Jacob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998;339:1994-2004
- Wilson DM, Baker B, Hintz RL, et al. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response. Pediatrics 1985;76:361-4
- MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone deficient children. J Clin Endocrinol Metab 1996;811:1806-9
- Schneider U, Birnbacher R, Shober E. Painfulness of needle and jet injection in children with diabetes mellitus. Eur J Pediatr 1994;153:409-10
- Gluckman PD, Cutfield WS. Evaluation of a pen injector system for growth hormone treatment. Arch Dis Child 1991;66:686-8
- Jørgensen JT. Improvement in patient convenience in treatment with growth hormone. J Pediatr Endocrinol 1994;7:175-80
- Bareille P, MacSwiney M, Albanese A, et al. Growth hormone treatment without a needle using the Preci-Jet 50 transjector. Arch Dis Child 1997;76:65-7
- Verrips GH, Hirasing RA, Fekkes M, et al. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Acta Paediatr 1998;87:154-8
- Silverstein JH, Murray FT, Malasanos T, et al. Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine 2001;15:15-17
- Stanhope R, Albanese A, Moyle L, et al. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Arch Dis Child 1992;67:994-7
- Sjöblom K, Albertsson-Wikland K, Bengtsson BA, et al. Patient evaluation of a new injection pen for growth hormone treatment in children and adults. Acta Paediatr Suppl 1995;411:63-5
- Wickramasuriya BP, Casey A, Akhtar S, et al. Factors determining patient choice of device for GH therapy. Horm Res 2006;65:18-22
- Dahlgren J, Veimo D, Johansson L, et al. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use. Curr Med Res Opin 2007;23:1649-55
- Dumas H, Panayiotopoulos P, Parker D, et al. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 2006;6:5
- Fuchs GS, Mikkelsen S, Knudsen TK, et al. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther 2009;31:2906-14
- Pfützner A, Hartmann K, Winter F, et al. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of study of three delivery devices in growth hormone-treated pediatric patients. Clin Ther 2010;32:1918-34
- Ahmed SF, Smith WA, Blamires C. Facilitating and understanding the family’s choice of injection device for growth hormone therapy by using conjoint analysis. Arch Dis Child 2008;93:110-14
- Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008;10:348-54
- Peyrot M, Rubin RR. Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The Insulin Delivery System Rating Questionnaire. Diabetes Care 2005;28:53-8
- U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
- Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30:307-16
- Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93:147-8
- Oyarzabal M, Aliaga M, Chuecha M, et al., on behalf of the Collaborative Group. Multicentre survey on compliance with growth hormone therapy: what can be improved? Acta Paediatr 1998;87:387-91